ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
4.880
+0.080 (1.67%)
At close: Mar 11, 2026, 4:00 PM EDT
4.960
+0.080 (1.64%)
After-hours: Mar 11, 2026, 7:56 PM EDT

ADC Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
81.3670.8469.56209.9133.92
Revenue Growth (YoY)
14.85%1.84%-66.86%518.89%-
Cost of Revenue
5.85.952.533.31.39
Gross Profit
75.5664.8967.03206.6132.52
Selling, General & Admin
79.9385.91105.89143.49136.24
Research & Development
104.01109.63127.13186.46158
Other Operating Expenses
13.12----
Total Operating Expenses
197.06195.54233.02329.95294.24
Operating Income
-121.5-130.65-165.99-123.34-261.72
Interest Income
8.8112.2710.542.570.07
Interest Expense
-51.63-50.21-46.33-36.73-18.34
Other Non-Operating Income (Expense)
22.7112.466.3510.6928.49
Total Non-Operating Income (Expense)
-20.11-25.48-29.43-23.4710.22
Pretax Income
-141.61-156.14-195.42-146.82-251.51
Provision for Income Taxes
1.020.1739.110.23-21.48
Net Income
-142.62-157.85-240.05-157.13-230.03
Minority Interest in Earnings
-1.545.5310.08-
Net Income to Common
-142.62-157.85-240.05-157.13-230.03
Shares Outstanding (Basic)
12797827877
Shares Outstanding (Diluted)
12797827877
Shares Change (YoY)
30.78%18.91%4.55%1.83%17.33%
EPS (Basic)
-1.12-1.62-2.94-2.01-3.00
EPS (Diluted)
-1.12-1.62-2.94-2.01-3.00
Free Cash Flow
-141.44-124.7-121.9-139-236.81
Free Cash Flow Per Share
-1.11-1.28-1.49-1.78-3.09
Gross Margin
92.87%91.60%96.36%98.43%95.89%
Operating Margin
-149.34%-184.44%-238.63%-58.76%-771.65%
Profit Margin
-175.31%-220.65%-337.16%-70.05%-678.20%
FCF Margin
-173.85%-176.04%-175.25%-66.22%-698.20%
EBITDA
-119.62-127.38-162.72-120.96-259.09
EBITDA Margin
-147.03%-179.82%-233.93%-57.62%-763.89%
EBIT
-121.5-130.65-165.99-123.34-261.72
EBIT Margin
-149.34%-184.44%-238.63%-58.76%-771.65%
Effective Tax Rate
-0.72%-0.11%-20.01%-0.15%8.54%
Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q